Menu Search
Equities

Diagnostic Medical Systems SA

DMS1:FRA

Diagnostic Medical Systems SA

Actions
  • Price (EUR)0.728
  • Today's Change-0.012 / -1.62%
  • Shares traded--
  • 1 Year change-19.65%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

DIAGNOSTIC MEDICAL SYSTEMS SA, (formerly known as DMS), is a France-based company, which together with its subsidiaries, designs, produces and markets medical imagery devices dedicated to conventional and digital radiology as well as bone densitometry. The Company manufactures a range of products for bone densitometry examination, including the ultrasound imaging system UBIS 5000, Challenger Envision, Stratos dR and Stratos. In the radiology sector, its products include Baccara dRF 43, EOL, Platinum and Da Vinci solutions, among others. In addition, it offers such products as scanners, transcranial Doppler, and Giotto Image mammography system. The Company operates several direct subsidiaries, AXS Medical, Apelem SAS, which manufactures radiology equipment, Medilink SARL, which produces Doppler and bone densitometry devices, Apelem SA, based in Spain, Alpha MOS based in France and one indirect subsidiary, SA Apelem and one indirect affiliated company, Spectrap.

  • Revenue in EUR (TTM)44.21m
  • Net income in EUR-14.97m
  • Incorporated1993
  • Employees143.00
  • Location
    Diagnostic Medical Systems SA9 Avenue du Canal PhilippeGALLARGUES-LE-MONTUEUX 30660FranceFRA
  • Phone+33 467504900
  • Fax+33 467504909
  • Websitehttps://www.dms.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.